Project Grant R21CA291724
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$186K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $1,305,116 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research program) will support a cell-based high-throughput screening (HTS) campaign to identify negative allosteric modulators of the Bruton's tyrosine kinase (BTK) enzyme. The principal investigators at the University of Pittsburgh will develop and optimize assays to screen for compounds that block BTK dimerization, a critical step in BTK activation. This aims to discover new small...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded a $502,516 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Case Western Reserve University's Office of Research Administration. This 5-year grant, starting on April 1, 2025, aims to further investigate the impacts of newly developed small molecule degraders that target the nuclear-specific Heat Shock Transcription Factor 1 (HSF1) on leukemic stem cell self-renewal in...
This $517,618 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Pittsburgh to examine the role of the TREM1 immune receptor in leukemia-associated macrophages (LAMs) and their interactions with leukemia stem cells. The key objectives are to: 1) investigate how TREM1 in LAMs promotes leukemia development, and 2) study the functional interplay between TREM1-positive LAMs and leukemia stem cells. This...
This $439,644 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports fundamental scientific investigations into the molecular and cellular mechanisms underlying acute myeloid leukemia (AML). The primary objectives are to: 1) investigate the relationship between specific mutations and leukemia stem cell frequency, disease initiation, and disease maintenance; 2) evaluate in vivo dynamics of individual AML stem cells using single-cell...
This federal Project Grant award of $614,749.00 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate the therapeutic potential and mechanistic actions of the PSPC1 protein in acute myeloid leukemia (AML).
The key objectives of the research are to: 1) elucidate the developmental and functional roles of PSPC1 in AML pathogenesis through genetically engineered...
This Federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Duke University is for $122,834 and will run from December 1, 2024 to May 31, 2026. The grant supports research to investigate how inhibition of ABL kinases affects metabolic function and dysregulation in small cell lung cancer (SCLC), and how combining ABL kinase inhibition with inhibition of MCT transporters may induce ferroptotic cell death in SCLC. The research aims to determine...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $144,056 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research aimed at quantitatively predicting drug-resistant kinase mutations in cancer. The overarching goal is to develop computational models that can forecast the impact of clinically observed kinase mutations on inhibitor resistance, sensitivity, and susceptibility. This will involve using binding...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the development of novel inhibitors and proteolysis targeting chimeras (PROTACs) that target the ENL protein, a key driver of acute myeloid leukemia (AML) with mixed-lineage leukemia (MLL) gene rearrangements. The $476,558 award to Texas A&M University aims to: 1) develop more potent, stable, and selective small molecule ENL inhibitors and PROTACs; 2)...
This $389,988 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research on the role of tRNA modifications in regulating cancer stem cell (CSC) biology in glioblastoma (GBM). The University of Pittsburgh, the prime awardee, will use mass spectrometry and ribosome profiling techniques to study how altered tRNA modification patterns impact translational reprogramming and drive oncogenic processes in GBM CSCs. The...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $443,220 in funding to the Beckman Research Institute of the City of Hope to study the role, mechanism, and therapeutic potential of the RNA methyltransferase METTL1 in acute myeloid leukemia (AML). The research aims to: 1) further consolidate the importance of METTL1 function in AML using mouse models, 2) understand the role of the METTL1/tRNAPheGAA/HCK signaling axis...